The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population

Kidney International, Supplement

Volumn 67, Issue 94, 2005, Pages

  Gansevoort, Ron T ^a   Verhave, Jacobien C ^b   Hillege, Hans L ^b   Burgerhof, Johannes G M ^b   Bakker, Stephan J L ^b   De Zeeuw, Dick ^b   De Jong, Paul E ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Albuminuria; Creatinine; Microalbuminuria; PREVEND; Screening; Sensitivity; Specificity

Indexed keywords

ALBUMIN; CREATININE;

ADULT; AGED; ANALYTIC METHOD; AREA UNDER THE CURVE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEINURIA; ROC CURVE; SENSITIVITY AND SPECIFICITY; URINALYSIS; VALIDATION PROCESS; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; STANDARD; URINE; VALIDATION STUDY; POPULATION; SCREENING; STATISTICAL ANALYSIS; VALIDITY;

ADULT; AGED; ALBUMINURIA; CREATININE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 15944422807     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
2. ROSSING P, HOUGAARD P, BORCH-JOHNSEN K, PARVING HH: Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 313:779-384, 1996
3. GERSTEIN HC, MANN JF, YI Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
4. VIBERTI GC, HILL RD, JARRETT RJ, et al: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1:1430-1432, 1982
5. ROMUNDSTAD S, HOLMEN J, KVENILD K, et al: Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis 42:466-473, 2003
6. JAGER A, KOSTENSE PJ, RUHE HG, et al: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study. Arteriosder Thromb Vasc Biol 19:617-624, 1999
7. HILLEGE HL, FIDLER V, DIERCKS GF, et al: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777-1782, 2002
8. AMERICAN DIABETES ASSOCIATION: Diabetic nephropathy. Diabetes Care 25:S85-S89, 2002
9. KEANE WF, EKNOYAN G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 33:1004-1010, 1999
10. PINTO-SIETSMA SJ, JANSSEN WM, HILLEGE HL, et al: Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 11:1882-1888, 2000
11. HILLEGE HL, JANSSEN WM, BAK AA, et al: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249:519-526, 2001
12. GARDNER MJ, ALTMAN DG: Calculating confidence intervals for proportions and their differences, in Statistics with Confidence: Confidence Intervals and Statistical Guidelines, edited by Gardner MJ, Altman DG, London, BMJ, 1989, pp 28-33
13. ALTMAN DG (editor): Practical Statistics for Medical Research, London, 1999, pp 415
14. CONNELL SJ, HOLLIS S, TIESZEN KL, et al: Gender and the clinical usefulness of the albumin:creatinine ratio. Diabet Med 11:32-36, 1994
15. HOULIHAN CA, TSALAMANDRIS C, AKDENIZ A, JERUMS G: Albumin to creatinine ratio: A screening test with limitations. Am J Kidney Dis 39:1183-1189, 2002
16. JACOBS DR, MURTAUGH MA, STEFFES M, et al: Gender- and race-specific determination of albumin excretion rate using albumin-to-creatinine ratio in single, untimed urine specimens. Am J Epidemiol 155:1114-1119, 2002
17. MATTIX HJ, HSU CY, SHAYKEVICH S, CURHAN G: Use of the albumin/creatinine ratio to detect microalbuminuria: Implications of sex and race. J Am Soc Nephrol 13:1034-1039, 2002
18. WARRAM JH, GEARIN G, LAFFEL L, KROLEWSKI AS: Effect of duration of type 1 diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7:930-937, 199
19. DERHASCHNIG U, KITTLER H, WOISETSCHLAGER C, et al: Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients? Nephrol Dial Transplant 17:81-85, 2002
20. JENSEN JS, CLAUSEN P, BORCH-JOHNSEN K, et al: Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 12(Suppl 2):6-9, 1997
21. TOWNSEND JC: Albumin to creatinine ratio: An unreliable index of 24 h albumin excretion in healthy adults. N Z Med J 100:66-67, 1987
22. MOORE RR, JR., HIRATA-DULAS CA, KASISKE BL: Use of urine specific gravity to improve screening for albuminuria. Kidney Int 52:240-243, 1997
23. NEWMAN DJ, PUGIA MJ, LOTT JA, et al: Urinary protein and albumin excretion corrected by creatinine and specific gravity. Clin Chim Acta 294:139-155, 2000
24. BAKKER AJ: Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 22:307-313, 1999
25. HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
26. HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 342:145-153, 2000
27. ASSELBERGS FW, DIERCKS GFH, HILLEGE HL, et al, ON BEHALF OF THE PREVEND IT INVESTIGATORS: Effects of fosinopril and pravastatin on cardiovascular events in microalbuminuric subjects without hypertension and hypercholesterolemia: A single-center, double-blind, randomised, placebo-controlled trial with 2 × 2 factorial design (PREVEND IT). Circulation 108:2723(A), 2003
28. BOULWARE LE, JAAR BG, TARVER-CARR ME, et al: Screening for proteinuria in US adults. A cost-effectiveness analysis. JAMA 290:3101-3114, 2003
29. GANSEVOORT RT, DE JONG PE, POSTMA MJ: Cost-effectiveness of screening for proteinuria. JAMA 291:1442-1443, 2004